Reduced high-sensitivity C-reactive protein levels following weekly somapacitan in adults with growth hormone deficiency: a prospective pilot study.

Seki Y, Morimoto S, Ikemoto M, Takebe S, Kitayama S, Hirata K, Takano N, Watanabe D, Ichihara A

Journal of endocrinological investigation29 Jul 2025Cited by 2 (Europe PMC)

PMID40728708DOI10.1007/s40618-025-02664-8PepBankPUB-40728708

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with GHD, hs-CRP decreased significantly from baseline after somapacitan therapy.
In plain wordsIn adults with GHD, hs-CRP decreased from baseline after somapacitan therapy.
Peptide
Somapacitan
Outcome
Decreasehs-CRP
Study
n = 13
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
hs-CRP
0.24 mg/dL
baseline
Range
0.07 to 0.51 mg/dL
baseline
hs-CRP
0.07 mg/dL
after treatment
Range
0.06 to 0.25 mg/dL
after treatment
P
< 0.001
Source sentences
Summary
Among 13 adult patients with GHD (9 men; 10 with adult-onset GHD), serum hs-CRP levels significantly decreased following somapacitan therapy (0.24 [0.07-0.51] to 0.07 [0.06-0.25] mg/dL, P <.001),
1 context sentence(design, population, supporting numbers)
Summary · context
This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.
Report a problemFND-4072870801
02HumanNon-randomized trialEfficacy outcome
In adults with GHD, IGF-1 increased significantly from baseline after somapacitan therapy.
In plain wordsIn adults with GHD, IGF-1 increased from baseline after somapacitan therapy.
Peptide
Somapacitan
Outcome
IncreaseIGF-1 levels
Study
n = 13
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
IGF-1
80 ng/mL
baseline
SD
53 ng/mL
baseline
IGF-1
148 ng/mL
after treatment
SD
74 ng/mL
after treatment
P
< 0.001
Source sentences
Summary
whereas serum insulin-like growth factor (IGF)-1 levels (80 ± 53 to 148 ± 74 ng/mL, P <.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.
Report a problemFND-4072870802
03HumanNon-randomized trialEfficacy outcome
In adults with GHD, IGF-1 SD scores increased significantly from baseline after somapacitan therapy.
In plain wordsIn adults with GHD, IGF-1 SD scores increased from baseline after somapacitan therapy.
Peptide
Somapacitan
Outcome
IncreaseIGF-1 SD scores
Study
n = 13
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
IGF-1 SDS
−2.8
baseline
SD
2.3
baseline
IGF-1 SDS
−0.4
after treatment
SD
1.7
after treatment
P
< 0.001
Source sentences
Summary
and IGF-1 SD scores (- 2.8 ± 2.3 to - 0.4 ± 1.7, P <.001) significantly increased.
1 context sentence(design, population, supporting numbers)
Summary · context
This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.
Report a problemFND-4072870803
04HumanNon-randomized trialEfficacy outcome
In adults with GHD, AST decreased slightly after somapacitan, without statistical significance.
In plain wordsIn adults with GHD, AST decreased slightly after somapacitan, but the change was not statistically significant.
Peptide
Somapacitan
Outcome
DecreaseAST
Study
n = 13
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels showed slight but statistically insignificant decreases after the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.
Report a problemFND-4072870804
05HumanNon-randomized trialEfficacy outcome
In adults with GHD, ALT decreased slightly after somapacitan, without statistical significance.
In plain wordsIn adults with GHD, ALT decreased slightly after somapacitan, but the change was not statistically significant.
Peptide
Somapacitan
Outcome
DecreaseALT
Study
n = 13
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels showed slight but statistically insignificant decreases after the treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.
Report a problemFND-4072870805
06HumanObservational studyOther
In adults with GHD receiving somapacitan, hs-CRP changes correlated inversely with IGF-1 SD score changes.
In plain wordsIn adults receiving somapacitan, greater IGF-1 SD score increases were linked to greater hs-CRP decreases.
Peptide
Somapacitan
Outcome
Decreasehs-CRP and IGF-1 SDS correlation
Study
n = 13
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
r
−0.66
P
0.01
Source sentences
Summary
Changes in hs-CRP levels correlated significantly with changes in IGF-1 SD scores (r = -.66, P =.01), AST (r =.67, P =.01), and ALT (r =.74, P =.004).
1 context sentence(design, population, supporting numbers)
Summary · context
This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.
Report a problemFND-4072870806
07HumanObservational studyOther
In adults with GHD receiving somapacitan, hs-CRP changes correlated positively with AST changes.
In plain wordsIn adults receiving somapacitan, hs-CRP changes were positively linked to AST changes.
Peptide
Somapacitan
Outcome
Increasehs-CRP and AST correlation
Study
n = 13
Outcome group
Inflammation markers · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
r
0.67
P
0.01
Source sentences
Summary
Changes in hs-CRP levels correlated significantly with changes in IGF-1 SD scores (r = -.66, P =.01), AST (r =.67, P =.01), and ALT (r =.74, P =.004).
1 context sentence(design, population, supporting numbers)
Summary · context
This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.
Report a problemFND-4072870807
08HumanObservational studyOther
In adults with GHD receiving somapacitan, hs-CRP changes correlated positively with ALT changes.
In plain wordsIn adults receiving somapacitan, hs-CRP changes were positively linked to ALT changes.
Peptide
Somapacitan
Outcome
Increasehs-CRP and ALT correlation
Study
n = 13
Outcome group
Inflammation markers · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
r
0.74
P
0.004
Source sentences
Summary
Changes in hs-CRP levels correlated significantly with changes in IGF-1 SD scores (r = -.66, P =.01), AST (r =.67, P =.01), and ALT (r =.74, P =.004).
1 context sentence(design, population, supporting numbers)
Summary · context
This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.
Report a problemFND-4072870808
09HumanObservational studyOther
In adults receiving somapacitan, hs-CRP changes remained associated with ALT changes independently of IGF-1 SD score changes.
In plain wordsIn adults receiving somapacitan, hs-CRP changes remained linked to ALT changes after adjustment for IGF-1 SD score changes.
Peptide
Somapacitan
Outcome
IncreaseAdjusted hs-CRP and ALT correlation
Study
n = 13
Outcome group
Inflammation markers · Liver
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
r
0.59
P
0.04
Source sentences
Summary
In partial correlation analyses, changes in hs-CRP levels remained significantly associated with ALT changes (r =.59, P =.04), independent of IGF-1 SD score changes.
1 context sentence(design, population, supporting numbers)
Summary · context
This study prospectively evaluated serum hs-CRP levels and metabolic parameters in adult patients with untreated GHD during a 6-month course of weekly somapacitan therapy.
Report a problemFND-4072870809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.